Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

July 26, 2022

Study Completion Date

July 26, 2022

Conditions
Short Bowel Syndrome
Interventions
DRUG

glepaglutide

Glucagon-Like Peptide-2 (GLP-2) analog

DRUG

Placebo

Placebo for glepaglutide

Trial Locations (29)

9000

Aalborg University Hospital, Aalborg

10029

Mount Sinai Hospital, New York

20007

Georgetown University Medical Center, Washington D.C.

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic College of Medicine, Rochester

60637

University of Chicago Children's Hospital, Chicago

68198-3285

University of Nebraska Medical Center, Omaha

Vanderbilt University Medical Center, Nashville, Nashville

Unknown

UZ Leuven, Leuven

The Royal Alexandra Hospital, Edmonton

University Health Network - Toronto General Hospital, Toronto

Rigshospitalet, Copenhagen

Hôpital Beaujon, Clichy

Centre Hospitalier Lyon-Sud, Pierre-Bénite

Charité - Universitätsmedizin Berlin, Berlin

Universitätsklinikum Bonn, Bonn

Universitätsklinikum Frankfurt - Med. Klinik I, Frankfurt

Asklepios Kliniken Hamburg GmbH, Hamburg

Universitätsmedizin Rostock, Rostock

UMC Radboud Nijmegen, Nijmegen

Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi, Lodz

Solumed, Poznan

Szpital Skawina sp. z o.o. im. Stanley Dudricka, Skawina

St Mark's Hospital, Harrow

UCLH Foundation NHS Trust, London

Salford Royal NHS Foundation Trust, Manchester

University of East Anglia, Norwich

University Hospital Southampton NHS Foundation Trust, Southampton

N6A 4V2

Western University, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zealand Pharma

INDUSTRY